Day One Biopharmaceuticals, Inc. (DAWN) Research

Operating as a clinical-stage biopharmaceutical entity, Day One Biopharmaceuticals, Inc. is dedicated to discovering and commercializing precise therapeutic options for individuals battling genetically defined cancers. A key asset is DAY101, an orally administered, brain-permeable type II pan-rapidly accelerated fibrosarcoma kinase inhibitor, currently undergoing Phase II clinical trials for young patients experiencing recurrent or worsening low-grade glioma. Additionally, the company is advancing Pimasertib, an oral small molecule designed to inhibit mitogen-activated protein kinase kinases 1 and 2. Established in 2018, Day One Biopharmaceuticals, Inc. maintains its primary operations in South San Francisco, California.

Market snapshot

Symbol
DAWN
Price
$21.53
Day change
0.00%
Market cap
$2.2B
P/E ratio
-20.74x
52-week range
5.635-21.53
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$21.50

Peer companies

  • Arvinas, Inc. (ARVN)
  • Astria Therapeutics, Inc. (ATXS)
  • ArriVent BioPharma, Inc. Common Stock (AVBP)
  • Erasca, Inc. (ERAS)
  • Geron Corporation (GERN)
  • Replimune Group, Inc. (REPL)
  • Rezolute, Inc. (RZLT)
  • Tyra Biosciences, Inc. (TYRA)

Recent insider activity

  • AI Day1 LLC — U-Tender (12929322 shares) on 2026-04-23
  • AI Day1 LLC — D-Return (827586 shares) on 2026-04-23
  • Bender Jeremy — D-Return (808285 shares) on 2026-04-23
  • Bender Jeremy — D-Return (286000 shares) on 2026-04-23
  • Bender Jeremy — D-Return (355000 shares) on 2026-04-23

Open Day One Biopharmaceuticals, Inc. (DAWN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.